Plasma adiponectin concentration and left ventricular hypertrophy in kidney transplant patients

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 561-568

  Adamczak, Marcin ^a   Blach, Anna ^a   Kolonko, Aureliusz ^a   Szotowska, Magdalena ^a   Chudek, Jerzy ^a   Franek, Edward ^b,c   Wiecek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Adiponectin; Intima media thickness; Kidney transplant patients; Left ventricular hypertrophy; Left ventricular mass

Indexed keywords

ADIPONECTIN; GLUCOSE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; CAROTID ARTERY, COMMON; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TUNICA INTIMA;

EID: 80051678536     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01330.x     Document Type: Article

References (56)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998: 32(Suppl 3): S112.
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003: 108: 2154.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990: 322: 1561.
4. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998: 97: 48.
5. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002: 40: 1202.
6. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989: 36: 286.
7. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003: 14: 462.
8. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001: 12: 1079.
9. Felicio JS, Ferreira SR, Plavnik FL et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 2000: 13: 1149.
10. Osorio Moratalla JM, Ferreyra Lanatta C, Baca Morilla Y et al. Left ventricular structure and function in long-term kidney transplantation: the influence of glucose metabolism and oxidative stress. Transplant Proc 2008: 40: 2912.
11. Wiecek A, Adamczak M, Chudek J. Adiponectin an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007: 22: 981.
12. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005: 6: 13.
13. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999: 257: 79.
14. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003: 423: 762.
15. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 1999: 100: 2473.
16. Wang B, Trayhurn P. Acute and prolonged effects of TNF alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006: 452: 418.
17. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005: 25: 2062.
18. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004: 316: 924.
19. Kobashi C, Urakaze M, Kishida M et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005: 97: 1245.
20. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004: 315: 264.
21. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest 2006: 116: 1784.
22. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001: 7: 941.
23. Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005: 48: 132.
24. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005: 46: 1369.
25. Baýes B, Lauzurica R, Granada ML et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004: 78: 26.
26. Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005: 67: 705.
27. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004: 10: 1384.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 16: 461.
29. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977: 55: 613.
30. Dereveux RB, Lutas EM, Casale PN et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984: 4: 1222.
31. Koren MJ, Dereveux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991: 114: 345.
32. Tikhonoff V, Casiglia E. Evolving concepts of left ventricular hypertrophy. Eur Heart J 2008: 29: 846.
33. Kozakova M, Muscelli E, Flyvbjerg A et al. Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab 2008: 93: 2811.
34. Ybarra J, Pou JM, Planas F et al. Correlation between insulin resistance surrogates and echocardiographic findings in asymptomatic patients with morbid obesity: a cross-sectional study. Endocr Pract 2007: 13: 590.
35. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004: 13: 236.
36. Mitsuhashi H, Yatsuya H, Tamakoshi K et al. Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 2007: 49: 1448.
37. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988: 108: 7.
38. Genís BB, Granada ML, Alonso N et al. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation 2007: 84: 1248.
39. Störk S, Bots ML, Angerer P et al. Low levels of adiponectin predict worsening of arterial morphology and function. Atherosclerosis 2007: 194: e147.
40. Lo J, Dolan SE, Kanter JR et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab 2006: 91: 1677.
41. Shargorodsky M, Boaz M, Goldberg Y et al. Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes (Lond) 2009: 33: 553.
42. Mangge H, Almer G, Haj-Yahya S et al. Preatherosclerosis and adiponectin subfractions in obese adolescents. Obesity (Silver Spring) 2008: 16: 2578.
43. Dullaart RP, De Vries R, Van Tol A, Sluiter WJ. Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender. Eur J Endocrinol 2007: 156: 387.
44. Kiris I, Tekin I, Yesildag A et al. Inverse relationship between adiponectin levels and subclinical carotid atherosclerosis in patients undergoing coronary artery bypass grafting. Int Heart J 2006: 47: 855.
45. Litwin M, ŚLadowska J, Antoniewicz J et al. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens 2007: 20: 875.
46. Nilsson PM, Engström G, Hedblad B et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006: 26: 2758.
47. Behre CJ, Brohall G, Hulthe J, Wikstrand J, Fagerberg B. Are serum adiponectin concentrations in a population sample of 64-year-old Caucasian women with varying glucose tolerance associated with ultrasound-assessed atherosclerosis? J Intern Med 2006: 260: 238.
48. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke 2005: 36: 2577.
49. Gardin JM, Wagenknecht LE, Anton-Culver H et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary Artery Risk Development in Young Adults. Circulation 1995: 92: 380.
50. Frankel DS, Vasan RS, D'Agostino RB Sr et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009: 53: 754.
51. Nanayakkara PW, Le Poole CY, Fouque D et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease. Clin Nephrol 2009: 72: 21.
52. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A. Plasma adiponectin concentration in patients after successful kidney transplantation - a single-center, observational study. Clin Nephrol 2007: 67: 381.
53. Adamczak M, Chudek J, Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial 2009: 22: 391.
54. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003: 46: 459.
55. Malyszko J, Malyszko J, Wolczynski S, Myśliwiec M.Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related? Nephrol Dial Transplant 2006: 21: 145.
56. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, for the MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007: 71: 1279.